Velpanat 400/100 mg (Sofosbuvir/Velpatasvir)

Velpanat 400/100 mg (Sofosbuvir/Velpatasvir) – A Comprehensive Guide

Brand Name: Velpanat
Generic Name: Sofosbuvir 400 mg + Velpatasvir 100 mg
Manufacturer: Natco Pharma Ltd.
Packaging: 28 tablets per bottle
Therapeutic Class: Antiviral (Direct-Acting Antiviral – DAA)
Indication: Chronic Hepatitis C Virus (HCV) infection

Overview

Velpanat 400/100 mg is a fixed-dose combination antiviral medicine created by Natco Pharma is developed to combat persistent Hepatitis C virus (HCV) infection across the six genotypes. It blends Sofosbuvir (400 mg) and Velpatasvir (100 mg)–two potent direct-acting antiviral (DAA) agents that act in synergy to stop the spread of the virus within the body. Velpanat is widely recognized as a reliable, safe, as well as accessibility, particularly in areas where the affordability of treatment is essential.

The tablet, which is taken once a day, forms part of the modern HCV treatment strategies that have the highest cure rate (SVR – sustained virologic response) with no unwanted side effects. It is also an innovation in global HCV treatment.

Components and Mechanism of Action

Sofosbuvir (400 mg)

Sofosbuvir is a nucleotide analog that inhibits the HCV NS5B RNA-dependent polymerase. It’s incorporated into the virus’s RNA and functions as a chain termination agent, which stops the virus from reproducing.

Velpatasvir (100 mg)

Velpatasvir is an NS5A inhibitor and inhibits the activity of the NS5A protein, a key component in virus replication as well as assembly. Velpatasvir increases the efficacy of Sofosbuvir. It also allows the combination to affect all of the major HCV strains (1-6).

Together, these two substances create Velpanat as the first pan-genotypic treatment that acts against all types of Hepatitis C. This simplifies the process of treating and reduces the need to test for genotype in a lot of cases.

Indications

Velpanat is recommended for the therapy for persistent Hepatitis C inflammation in children and adults (age ≥6 years or weighing ≥17 kg) and with or without compensatory liver cirrhosis (Child-Pugh A).

It can also be utilized in specific cases of decompensated liver disease (Child-Pugh B and C) in conjunction with Ribavirin under the supervision of a medical professional.

Dosage and Administration

Recommended Dosage:

• One tablet (400 mg Sofosbuvir + 100 mg Velpatasvir) once daily
• The medication can be administered in combination with or without food
• Treatment duration: 12 weeks for most patients
• For certain patients (e.g., patients who have decompensated cirrhosis), Ribavirin can be added to the treatment, and the time frame for treatment can vary

Note: Always adhere to your doctor’s instructions and prescriptions.

Who Should Take Velpanat?

Velpanat is suitable for:

• Treatment-naïve or treatment-experienced patients
• People who are infected with one of the 6 HCV genotypes
• People who are co-infected by HIV/HCV
• Patients who suffer from kidney impairment (including dialysis) — no dose adjustments are required.

Who Should NOT Take Velpanat?

Do not use Velpanat if you:

• Are you allergic to Sofosbuvir, Velpatasvir, or other ingredients included in the formula
• Are you taking certain medications like Rifampin, Carbamazepine, St. John’s Wort, or any other potent enzyme stimulants
• Are you pregnant or breastfeeding without a consultation with your doctor

Common Drug Interactions

Velpanat may interact with:

• Antacids, proton pump inhibitors (PPIs), and H2 blockers – decrease absorption of Velpatasvir
• Amiodarone – the risk of developing symptomatic bradycardia is very high, associated with the use of Sofosbuvir
• Anticonvulsants (Phenytoin, Carbamazepine)
• HIV medications like Efavirenz and Tenofovir

Make sure you provide your doctor with the complete medication list, which includes prescription drugs as well as herbal supplements.

Side Effects

Velpanat is usually tolerated well. The most frequent side effects are:

• Fatigue
• Headache
• Nausea
• Insomnia
• Diarrhea

Serious side effects are rare but can include:

• Slow heart rate (especially when taken with Amiodarone)
• Allergic reactions
• Liver function abnormalities

Consult a doctor if you are experiencing symptoms that include excessive fatigue, a yellowing or sagging of the skin or eyes (jaundice), and/or difficulty breathing.

Clinical Efficacy

Numerous clinical trials have confirmed the high effectiveness of Sofosbuvir/Velpatasvir in achieving SVR (Sustained Virologic Response) — considered a cure for HCV.

SVR12 rates (12 weeks post-treatment):

• 95–99% across genotypes 1 to 6
• A high rate of cure, even for patients suffering from chronic cirrhosis, HIV co-infection, and impaired renal function

Velpanat is a basic, ribavirin-free, and non-interferon treatment that has a brief time-to-treatment and no need for monitoring.

Advantages of Velpanat

• Pan-genotypic: It is effective across all genotypes of HCV.
• High cure rate: >95% SVR in most cases
• Once-daily dosage: Convenient for adherence
• Ribavirin-free option: Minimizes side effects
• Affordable: Particularly in low or middle-income countries
• Well-tolerated: Mild side effect profile
• Simplified treatment: No need for genotype-specific regimens

Storage and Handling

• Store at room temperature (15°C – 30°C or 59°F – 86°F)
• Guard against the moisture as well as intense sunlight
• Make sure that the items are out of the reach of young children.
• Don’t use it past the expiration date

FAQs

Q1: Is Velpanat a cure for Hepatitis C?

Yes, attaining SVR12 after treatment is completed using Velpanat is believed to be a cure for virology in that the virus cannot be detected within your blood for 12 weeks following the time when treatment ends.

Q2: Can Velpanat be used in children?

Yes, Absolutely, Velpanat has been approved for use in children 6 years and over or who weigh 17kg or more with the guidance of a physician.

Q3: Do I need a prescription for Velpanat?

Yes, Absolutely, Velpanat is a prescription drug. It must be used only under supervision by a licensed medical professional.

Q4: Can I drink alcohol while on Velpanat?

Alcohol may worsen liver damage. It’s recommended to limit or reduce alcohol consumption in the course of or after treatments.

Availability and Access

Velpanat is offered in a variety of countries via governments, government programmes, NGOs, and online pharmacies. It’s a generic form of Epclusa (by Gilead Sciences) that is licensed to be manufactured and sold in low and middle-income countries in order to improve accessibility to inexpensive Hepatitis C treatments.

Before you purchase, be sure to purchase from certified and authorized suppliers to ensure that you do not purchase counterfeit goods.

Conclusion

Velpanat 400/100 mg is an innovative, affordable, and extremely effective antiviral therapy to treat long-term Hepatitis C. It provides an all-genotypic, once-daily, and tolerated medication; this is an important milestone in the fight against HCV.

Its accessibility, particularly in areas with limited resources, has allowed millions to get lifesaving treatments, bringing the dream of a C-free society a possibility.